Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 8/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2209014 | 0.93 | AVPR1A (0.53) | AVPR1AHSD11B1NPY5RHRH3LMNA | |
| SCHEMBL4980584 | 0.79 | AVPR1A (0.52) | AVPR1ANPY5RHRH3LMNAMAPT | |
| SCHEMBL3841668 | 0.76 | HRH3 (0.49) | AVPR1ANPY5RHRH3HPGDTP53 | |
| SCHEMBL3841971 | 0.76 | HTR1A (0.49) | AVPR1ANPY5RHRH3LMNAMAPT | |
| SCHEMBL3840207 | 0.75 | NPY5R (0.55) | AVPR1ANPY5RHRH3ALDH1A1POLB | |
| SCHEMBL4025618 | 0.74 | AVPR1A (0.47) | AVPR1ANPY5RHRH3LMNATHRB | |
| SCHEMBL22058131 | 0.74 | AVPR1A (0.55) | AVPR1ANPY5RHRH3ALDH1A1HPGD | |
| SCHEMBL4359848 | 0.72 | AVPR1A (0.61) | AVPR1AALDH1A1POLB | |
| SCHEMBL2212218 | 0.72 | HSD11B1 (0.47) | AVPR1AHSD11B1NPY5RHRH3LMNA | |
| SCHEMBL8182388 | 0.72 | HSD11B1 (0.47) | AVPR1AHSD11B1NPY5RHRH3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125726-B1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-07-27 | — | — | EP | disclosed |
| EP-2125726-B1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-7678806-B2 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678806-B2 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678806-B2 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7501432-B2 | Spiro-piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501432-B2 | Spiro-piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501432-B2 | Spiro-piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7495008-B2 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495008-B2 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080280898-A1 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280898-A1 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280898-A1 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080167333-A1 | NEW SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-07-10 | — | — | US | disclosed |
| US-20080167333-A1 | NEW SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-07-10 | — | — | US | disclosed |
| US-20080167333-A1 | NEW SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-07-10 | — | — | US | disclosed |
| US-20080161304-A1 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161304-A1 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161304-A1 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| WO-2008077811-A1 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161304-A1 | Spiro-piperidine derivatives | AVPR1A, AVPR1B, ADRA1A | AVPR1A 1/4885HSD11B1 1386/4885NPY5R 53/4885 |
| US-20080167333-A1 | NEW SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE | HTR1A, HTR5A, ADRA1A | AVPR1A 7/4885HSD11B1 1815/4885NPY5R 21/4885 |
| US-20080280898-A1 | Spiro-piperidine derivatives | AVPR1A, AVPR1B, ADRA1A | AVPR1A 1/4885HSD11B1 1386/4885NPY5R 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.